Millions of Americans aged 65 and older rely on Medicare Part D to manage the cost of their prescription medications. As the healthcare landscape shifts, this crucial benefit faces financial and structural changes that could significantly affect premiums in the coming year.
Premium increases projected for 2026 reflect a complex mix of policy reforms, drug market trends and federal funding adjustments. These developments could reshape how beneficiaries plan and budget for their medical needs—making careful review during the upcoming open enrollment period more critical than ever.
Drug Spending Trends and New Treatment Uptake Drive Premium Pressures
Monthly premiums for Medicare Part D are expected to rise significantly in 2026, with some plans potentially increasing by as much as $50, according to KFF Health News. These changes are projected to affect millions of beneficiaries who rely on stand-alone prescription drug plans, a key component of traditional Medicare introduced in 2006.
According to the American Journal of Health-System Pharmacy, total spending on prescription drugs across insurers and government programs rose by more than 10% in 2024, largely driven by higher volumes of use and the market entry of new, high-cost treatments.
Although overall drug prices showed a slight decrease, specific categories such as weight-loss medications and immunosuppressive therapies for autoimmune diseases saw considerable uptake. These are especially relevant for the Medicare population, many of whom manage chronic conditions like diabetes or rheumatoid arthritis.
Policy observers have noted that while Medicare currently does not cover drugs used primarily for weight loss, many of these treatments are used off-label for other covered indications. This trend, combined with increased utilization, places added financial pressure on insurers when projecting premium levels for future plans.
Another contributing factor is the ongoing impact of tariff policies under the Trump administration. The tariffs, which affect the importation of pharmaceuticals, could further influence pricing structures depending on how costs are passed down by manufacturers.
Policy Reforms Shift Cost Burden From Patients to Insurers
Structural changes introduced by the Inflation Reduction Act are also playing a key role in projected premium increases. Under the reforms, a $2,000 annual cap on out-of-pocket spending for prescription drugs came into effect in 2025, a significant reduction from previous years where beneficiaries could pay much more for high-cost treatments.
This new cap means that insurers are now responsible for a larger share of drug costs once the patient threshold is reached. As explained by Stacie Dusetzina, professor of health policy at Vanderbilt University Medical Center, “The Inflation Reduction Act was necessary to make Part D proper health insurance, but there’s a cost to do so.”
To mitigate the impact of these reforms, the Biden administration introduced a premium stabilization program, allocating over $6 billion to Part D insurers in 2025. The average monthly premium dropped from $43 to $39 as a result. However, the Trump administration has announced it will reduce this funding by 40% in 2026, leaving insurers with less support and increasing the potential for higher premiums.
As open enrolment begins on 15 October, experts advise all Medicare beneficiaries to reassess their plans carefully. With costs shifting and coverage conditions evolving, renewing an existing plan without review could result in unexpected expenses.
